Drug Information

Drug General Information
Drug ID
D0G4DE
Former ID
DNC000313
Drug Name
BIA 3-202
Drug Type
Small molecular drug
Indication Parkinson's disease [ICD9: 332; ICD10:G20] Phase 2 [529342]
Formula
C14H11NO5
Canonical SMILES
C1=CC=C(C=C1)CC(=O)C2=CC(=C(C(=C2)O)O)[N+](=O)[O-]
InChI
1S/C14H11NO5/c16-12(6-9-4-2-1-3-5-9)10-7-11(15(19)20)14(18)13(17)8-10/h1-5,7-8,17-18H,6H2
InChIKey
MRFOLGFFTUGAEB-UHFFFAOYSA-N
CAS Number
CAS 274925-86-9
PubChem Compound ID
9838389
PubChem Substance ID
14799384, 24137176, 44936477, 57373490, 79760348, 92729843, 103412732, 104004043, 125732769, 126601938, 128636293, 134343097, 135252377, 136345013, 137237662, 140030645, 163154452, 198940728, 226500751, 241056130
Target and Pathway
Target(s) Catechol-O-methyl-transferase Target Info Inhibitor [535563]
BioCyc Pathway L-dopa degradation
Dopamine degradation
Noradrenaline and adrenaline degradation
KEGG Pathway Steroid hormone biosynthesis
Tyrosine metabolism
Metabolic pathways
Dopaminergic synapse
PANTHER Pathway Adrenaline and noradrenaline biosynthesis
Dopamine receptor mediated signaling pathway
PathWhiz Pathway Tyrosine Metabolism
WikiPathways Methylation Pathways
Metapathway biotransformation
Estrogen metabolism
Biogenic Amine Synthesis
Dopamine metabolism
Phase II conjugation
Neurotransmitter Clearance In The Synaptic Cleft
References
Ref 529342Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease. Clin Neuropharmacol. 2008 Jan-Feb;31(1):2-18.
Ref 535563Chemical synthesis and characterization of conjugates of a novel catechol-O-methyltransferase inhibitor. Bioconjug Chem. 2002 Sep-Oct;13(5):1112-8.

If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.